# PLEGRIDY
Keywords: PLEGRIDY, peginterferon beta-1a, relapsing-remitting multiple sclerosis, RRMS, efficacy, convenience, family planning, immunogenicity, safety, tolerability

> This page provides detailed information about PLEGRIDY, a treatment for relapsing-remitting multiple sclerosis (RRMS), including its efficacy, convenience, safety, and use in specific patient scenarios such as family planning.

## Details
- [Efficacy](#): PLEGRIDY demonstrates proven and sustained long-term efficacy for RRMS patients, reducing relapse rates and achieving no evidence of disease activity (NEDA) in clinical studies.
- [Convenience](#): Offers the lowest dosing frequency among MS therapies, with fortnightly intramuscular or subcutaneous self-administration options.
- [Family Planning](#): Can be used during breastfeeding and may be considered during pregnancy if clinically needed, with limited data available on exposure during pregnancy.
- [Immunogenicity](#): Associated with low rates of immunogenicity, with less than 1% of patients developing persistent neutralizing antibodies over two years.
- [Safety and Tolerability](#): PLEGRIDY has a well-established safety profile observed in studies lasting up to five years.
- [Indication](#): Approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in adults.
- [Patient Profiles](#): Features examples of how PLEGRIDY supports diverse patient needs, such as family planning, convenience for busy lifestyles, and managing aging-related concerns in RRMS.